Company registration number 10207693 (England and Wales)
BIAL PHARMA UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
BIAL PHARMA UK LIMITED
COMPANY INFORMATION
Directors
M Ruiz
M Portela
A Portela
M Bricchi
Company number
10207693
Registered office
St Stephens House
Arthur Road
Windsor
Berkshire
SL4 1RU
Auditor
Two Rivers Accounting Services Limited
38 Eton Wick Road
Eton Wick
Windsor
Berkshire
SL4 6JL
BIAL PHARMA UK LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 7
BIAL PHARMA UK LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
2,535
3,359
Current assets
Debtors
4
771,454
298,713
Cash at bank and in hand
492,355
753,437
1,263,809
1,052,150
Creditors: amounts falling due within one year
5
(601,516)
(591,096)
Net current assets
662,293
461,054
Total assets less current liabilities
664,828
464,413
Provisions for liabilities
(634)
(839)
Net assets
664,194
463,574
Capital and reserves
Called up share capital
100,000
100,000
Profit and loss reserves
564,194
363,574
Total equity
664,194
463,574

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 14 April 2026 and are signed on its behalf by:
M Portela
Director
Company registration number 10207693 (England and Wales)
BIAL PHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
1
Accounting policies
Company information

Bial Pharma UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is St Stephens House, Arthur Road, Windsor, Berkshire, SL4 1RU and the company number is 10207693.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
12.5% Straight line
Computers
33% Straight line
1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and includes cash in hand.

BIAL PHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price (including transaction costs). Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans and loans from fellow group, are initially recognised at transaction price (including transaction costs). Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

BIAL PHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
20
22
BIAL PHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 5 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 January 2025 and 31 December 2025
16,583
Depreciation and impairment
At 1 January 2025
13,224
Depreciation charged in the year
824
At 31 December 2025
14,048
Carrying amount
At 31 December 2025
2,535
At 31 December 2024
3,359
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
-
0
30,966
Amounts owed by group undertakings
515,828
-
0
Other debtors
255,626
267,747
771,454
298,713
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
181,968
99,093
Amounts owed to group undertakings
-
0
108,100
Taxation and social security
48,350
122,945
Other creditors
371,198
260,958
601,516
591,096
6
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

BIAL PHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
6
Audit report information
(Continued)
- 6 -
Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Delia Allott FCCA
Statutory Auditor:
Two Rivers Accounting Services Limited
Date of audit report:
14 April 2026
BIAL PHARMA UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
7
Related party transactions
Transactions with related parties

The company has taken advantage of the exemption under FRS 102 Section 1A from disclosing related party transactions entered into under normal market conditions.

The parent of the largest group in which these financial statements are consolidated is BIAL HOLDING, S.A, incorporated in Portugal.

 

The registered and trading address of BIAL HOLDING, S.A is:

A Avenida Da Siderurgia Nacional

Coronado (S.Romao E S.Mamede)

Trofa

4745-457

Portugal

8
Parent company

The company's immediate parent is BIAL- HOLDING, S.A, incorporated in Portugal.

The ultimate controlling party of the company is Luís António Silva Duarte Portela.

2025-12-312025-01-01falsefalsefalse14 April 2026CCH SoftwareCCH Accounts Production 2025.100No description of principal activityM RuizM PortelaA PortelaM Bricchi102076932025-01-012025-12-3110207693bus:Director12025-01-012025-12-3110207693bus:Director22025-01-012025-12-3110207693bus:Director32025-01-012025-12-3110207693bus:Director42025-01-012025-12-3110207693bus:RegisteredOffice2025-01-012025-12-31102076932025-12-31102076932024-12-3110207693core:OtherPropertyPlantEquipment2025-12-3110207693core:OtherPropertyPlantEquipment2024-12-3110207693core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3110207693core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3110207693core:ShareCapital2025-12-3110207693core:ShareCapital2024-12-3110207693core:RetainedEarningsAccumulatedLosses2025-12-3110207693core:RetainedEarningsAccumulatedLosses2024-12-3110207693core:FurnitureFittings2025-01-012025-12-3110207693core:ComputerEquipment2025-01-012025-12-31102076932024-01-012024-12-3110207693core:OtherPropertyPlantEquipment2024-12-3110207693core:OtherPropertyPlantEquipment2025-01-012025-12-3110207693core:CurrentFinancialInstruments2025-12-3110207693core:CurrentFinancialInstruments2024-12-3110207693core:WithinOneYear2025-12-3110207693core:WithinOneYear2024-12-3110207693bus:PrivateLimitedCompanyLtd2025-01-012025-12-3110207693bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3110207693bus:FRS1022025-01-012025-12-3110207693bus:Audited2025-01-012025-12-3110207693bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP